001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Set to Join Russell Microcap® Index
June 08, 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is...
001_Delcath_CorporateLogo_Tagline.png
Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting
June 07, 2021 07:30 ET | Delcath Systems, Inc.
As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success Newly Disclosed Patient Level Data...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET
June 03, 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Present at Jefferies Virtual Healthcare Conference
May 26, 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Announces First Quarter 2021 Results
May 11, 2021 08:00 ET | Delcath Systems, Inc.
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results
April 30, 2021 16:01 ET | Delcath Systems, Inc.
NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 30, 2021 09:00 ET | Delcath Systems, Inc.
A Presentation of Positive Preliminary Efficacy Results from the FOCUS Phase III trial Company Q&A Webinar Scheduled for Monday, June 7, 2021 at 8:30am ET NEW YORK, April 30, 2021 ...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom
April 21, 2021 08:38 ET | Delcath Systems, Inc.
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation
March 31, 2021 14:55 ET | Delcath Systems, Inc.
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time
March 31, 2021 07:45 ET | Delcath Systems, Inc.
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...